Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.49 |
| ▸ | HCAR1 | Q9BXC0 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 3/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3171115 | 0.79 | ADORA2A (0.55) | LMNAADORA2AALDH1A1TSHRHSD17B10 | |
| SCHEMBL431906 | 0.76 | ADORA2A (0.57) | LMNAADORA2AADORA3ADORA1MAPT | |
| Isocaffiene SCHEMBL515995 | 0.73 | LMNA (0.57) | LMNAADORA2AALDH1A1KDM4ERAB9A | |
| SCHEMBL7437145 | 0.72 | GRIA1 (0.45) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL7436592 | 0.72 | GRIA1 (0.45) | ADORA2AALDH1A1KDM4ENPC1TSHR | |
| SCHEMBL8136340 | 0.70 | LMNA (0.54) | LMNAADORA2AALDH1A1KDM4ETSHR | |
| SCHEMBL3272841 | 0.70 | LMNA (0.54) | LMNAADORA2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL1962417 | 0.69 | LMNA (0.69) | LMNAADORA2AALDH1A1KDM4ERAB9A | |
| SCHEMBL18256136 | 0.69 | ADORA2B (0.60) | LMNAADORA2AADORA3ADORA1MAPT | |
| SCHEMBL23974581 | 0.68 | LMNA (0.58) | LMNAALDH1A1KDM4ETSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011057199-A1 | COMPOSITIONS FOR TREATING CNS DISORDERS | ADENIOS, INC. (US) | 2011-05-12 | — | — | WO | claimed |
| EP-1305328-A2 | MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES | Lyles, Mark B. (US) | 2003-05-02 | — | — | EP | claimed |
| WO-2002008237-A2 | MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES | LYLES MARK B (US) | 2002-01-31 | — | — | WO | claimed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2022-02-03 | — | — | US | disclosed |
| US-11208475-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210283217-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-16 | — | — | US | disclosed |
| US-11059886-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210177823-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-17 | — | — | US | disclosed |
| US-20210154272-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-05-27 | — | — | US | disclosed |
| US-11013717-B1 | Methods and compositions for treating cancer using SERCA pump inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20190240293-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | CYGNAL THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20190233527-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES OR CONDITIONS USING CALCITONIN RECEPTOR ACTIVATORS | FLAGSHIP PIONEERING, INC. | 2019-08-01 | — | — | US | disclosed |
| EP-2582374-A2 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | Afraxis, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2453896-A2 | METHODS FOR TREATING SCHIZOPHRENIA | Afraxis, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011159945-A2 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011009097-A2 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | CHRNA6, CHRNA1, CHRNB1 | LMNA 827/4885ADORA2A 90/4885HCAR1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.